Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Contracts Finder |
| Notice Type: | Award notice |
| Buyer: | Newcastle University |
| Main Category: | Services |
| Procurement Method: | Open procedure |
| Tender Status: | Closed |
| Estimated Value (ex. VAT): |
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Application Deadline
5 January 2023
Closed
Estimated Value
£2,000,000
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| £2,000,000 |
| Release Date: | 4 October 2023 |
| Application Deadline: | 5 January 2023 |
| Contract Start Date: | 28 September 2023 |
| Contract End Date: | 15 May 2028 |
| Contract Duration: | 4.7 years |
| Procurement ID (OCID): | ocds-b5fd17-9533e01f-2348-4ac8-b09b-e59daf393014 |
| Notice Reference: | 2038a9d9-a190-485b-ba95-4511aa9a5644-686154 |
View Original Notice
Access the full notice on the official portal
Awarded to
| Award value: | £2,002,000 |
| Award decision date: | 29 August 2023 |
| Award status: | Active |
The Newcastle University Translational and Clinical Research Institute is one of three research institutes established in 2019 following a restructure within the Faculty of Medical Sciences. Its members map across the biomedical research landscape. A number of major research projects are led from within the Institute including the "NASH Disease Translational Accelerator" (NASH-DTA) project. This project funded brings together clinicians and scientists from prominent academic centres across Europe and industrial partners to conduct research into advanced liver disease/cirrhosis caused by non-alcoholic fatty liver disease (NAFLD). Their common goals are developing, validating and qualifying better biomarkers for NAFLD. Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, NAFLD is an increasingly common cause of advanced liver disease that is characterized by substantial inter-patient variability in severity and rate of progression. Biomarkers under investigation in the project include genes that contribute to NAFLD progression. The purpose of this tender process is to engage a supplier to provide clinical research support, central laboratory services and to oversee biological sample transfers and provide centralised laboratory processing of biological samples collected during the course of the study.